Trials / Terminated
TerminatedNCT01750684
AC105 in Patients With Acute Traumatic Spinal Cord Injury
A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Determine the Safety, Tolerability and Potential Activity of AC105 Following a Regimen of 6 Doses Over 30 Hours in Patients With Acute Traumatic Spinal Cord Injury (SCI).
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Acorda Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The principal aim of this study was to establish the feasibility of rapid administration, safety, and tolerability of AC105 in patients with acute spinal cord injury.
Detailed description
To determine safety and tolerability of AC105 following a regimen of 6 intravenous doses over 30 hours in patients with acute non-penetrating traumatic spinal cord injury (SCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC105 | |
| OTHER | Placebo |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2015-02-01
- Completion
- 2015-05-01
- First posted
- 2012-12-17
- Last updated
- 2018-11-06
- Results posted
- 2016-06-13
Source: ClinicalTrials.gov record NCT01750684. Inclusion in this directory is not an endorsement.